Cas9 News and Research

RSS

StemSight and ERS Genomics focus on collaboration

License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindness.

17 Jan 2024

RBM5 identified as key regulator of HOXA9 in acute myeloid leukemia

The protein HOXA9 is overexpressed in most acute myeloid leukemia (AML) cases and is associated with poor patient outcomes.

12 Jan 2024

Breakthrough in gene editing: Enhanced virus-like particles promise new era in genetic disease treatment

Researchers developed an advanced prime editor-engineered virus-like particle (PE-eVLP) system, significantly enhancing gene editing efficiency in human cells and showing potential for treating genetic diseases.

9 Jan 2024

Marking a vital milestone for Vertex and Charles River

Charles River’s Memphis facility approved to manufacture Vertex’s CASGEVY™ therapy, the world’s first gene-edited therapy targeting severe sickle cell disease

From Charles River 9 Jan 2024

3D mini-organs from human fetal brain tissue unlock new frontier in brain research

Scientists have developed 3D mini-organs from human fetal brain tissue that self-organize in vitro. These lab-grown organoids open up a brand-new way of studying how the brain develops.

8 Jan 2024

Engineered virus-like particles power up gene editing, correcting blindness in mice

Prime editing, a versatile form of gene editing that can correct most known disease-causing genetic mutations, now has a new vehicle to deliver its machinery into cells in living animals.

8 Jan 2024

Revolutionary RNA-based switch offers new control over gene expression in mammalian cells

Researchers developed an RNA-based switch, the pA regulator system, to control gene expression in mammalian cells by modulating synthetic polyA signal cleavage, offering a novel approach for gene therapy applications.

4 Jan 2024

Study reveals cytoglobin's pivotal role in cilia movement and organ positioning during development

Study reveals that cytoglobin (cygb2) plays a crucial role in regulating cilia motility and organ laterality during development, highlighting its importance in NO signaling and cilia function.

19 Dec 2023

Key Charpentier/Doudna CRISPR patent upheld by Japanese Patent Office

Patent JP6692856 upheld for second time in response to invalidation challenge.

19 Dec 2023

CRISPR opens doors for novel probiotic functions and applications

Humans can benefit significantly from symbiotic relationships with probiotics-;live bacteria and microorganisms that influence the gut microbiota.

13 Dec 2023

Understanding how proteasome dysfunction contributes to age-related cognitive decline

About 40 percent of people over age 65 suffer some form of age-related memory loss, which puts them at higher risk for developing dementia and Alzheimer's disease.

13 Dec 2023

New study provides convincing evidence of the essential role of cylicins in sperm development and fertility

Researchers investigated the Role of Cylicins in Spermiogenesis and Male Fertility in Mice and Humans through Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9) Gene Editing.

30 Nov 2023

Researchers introduce CRISPR-mediated genome and cancer shredding as a conceptual paradigm to treat recurrent gliomas

Researchers demonstrated clustered regularly interspersed short palindromic repeats (CRISPR)-mediated elimination of glioblastoma (GBM) cells.

29 Nov 2023

Missing protein triggers alternative immune attack on cancer cells

Researchers at the UCLA Jonsson Comprehensive Cancer Center have found certain immune cells can still fight cancer even when the cancer cells lack an important protein that the immune system relies on to help track down cancer cells.

28 Nov 2023

Study finds diet-derived trans-vaccenic acid boosts anti-tumor immunity

Dietary components that impact anti-tumor immunity.

28 Nov 2023

Synthetic biologists develop versatile platform for targeted drug delivery

In recent years, cell and gene therapies have shown significant promise for treating cancer, cystic fibrosis, diabetes, heart disease, HIV/AIDS and other difficult-to-treat diseases.

27 Nov 2023

New CRISPR approach shows promise for treating glioblastoma

The gene-editing technology CRISPR shows early promise as a therapeutic strategy for the aggressive and difficult-to-treat brain cancer known as primary glioblastoma, according to findings of a new study from Gladstone Institutes.

27 Nov 2023

Bonn immunologist receives €2 million grant to harness the power of nanobodies for inflammation control

Bonn immunologist Prof. Florian I. Schmidt, who conducts research at the Institute of Innate Immunity at the University Hospital Bonn (UKB), has been awarded a Consolidator Grant from the European Research Council to fund his research project DEFLAMMATION with two million Euro.

23 Nov 2023

Scientists uncover key to enhancing cancer-killing T cells

T cells are the key immune system component involved in killing cancer. Tumors produce signals that turn off these T cells, partially by forcing them to progressively differentiate (mature) into a hypofunctional state known as exhaustion.

21 Nov 2023

New approach to CAR T cell therapy may extend treatment effectiveness

CAR T cell therapy, a powerful type of immunotherapy, has begun to revolutionize cancer treatment. Pioneered at Memorial Sloan Kettering Cancer Center (MSK), the therapy involves engineering a patient's T cells so they recognize and attack cancer cells.

14 Nov 2023